Kiora expands KIO-301 Phase 2 development after positive ABACUS-1 results; Q3 net loss $5.8M

KIORA PHARMACEUTICALS INC

2023-Q3 EPS reported -$2.73

ABACUS-1 Phase 1b showed KIO-301 safe, tolerable, with significant visual field improvements and increased brain activity on fMRI.
Company plans Phase 2 trials for RP (ABACUS-2), Choroideremia, and Stargardt disease in 2024.
Q3 2023 net loss $5.8M vs $5.1M in Q3 2022; loss increase driven by non-cash impairment of KIO-101/201.
Cash and equivalents $5.4M, plus $1.3M tax receivables; runway into May 2024; $9.6M available on equity line.
Raised $6.3M in funding and $1.2M in tax incentives during first half of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.